Articles related to BLEEDING/BLOOD DISORDERS

The surprising association between CHIP and a lowered risk of Alzheimer’s disease offers a novel perspective in our understanding of neurodegenerative disorders and paves the way for potential future therapeutics.

Enhancing Platelet Dysfunction Diagnosis with Platelet Function Screen The Platelet Function Screen (PFA-100®) is a critical in vitro system for detecting platelet dysfunction. It uses citrated whole blood samples under high shear flow conditions, demonstrating its sensitivity. As blood is aspirated through collagen-coated membranes, platelet adhesion forms an initial matrix. Adding to the mix, platelet aggregation is stimulated by either epinephrine (COL/EPI) or adenosine diphosphate (COL/ADP), coating the membranes. In this process, the time required to form a platelet plug that blocks the aperture, known as closure time (CT), is the key measure of platelet function. Interestingly, several conditions can cause prolonged CT, including drug effects, low hematocrit, thrombocytopenia, von Willebrand Disease (vWD), and platelet disorders. Notably, aspirin therapy impacts the COL/EPI closure time more than COL/ADP. While assessing results, hematological considerations are pivotal, particularly with anemia and thrombocytopenia that could extend CT. Platelet counts below 150,000/uL or hematocrit below 35% could interfere with the results, thus, the test might not serve patients with counts below 100,000/uL or hematocrit under 30%. Moreover, hematocrit over 50% could generate inconsistent outcomes. Fundamentally, normal CT with both COL/EPI and COL/ADP signifies healthy platelet function. The COL/EPI membrane, while sensitive to primary hemostasis disorders, […]

A 51-year-old man presents with a 10-week history of intermittent bright red blood per rectum. His medical history is unremarkable, and he takes no medications. Physical examination reveals normal vital signs and a normal digital rectal examination. Fecal occult blood is positive. A colonoscopy identifies a nonobstructing lesion located 10 cm from the anal verge, while the rest of the colon appears normal. MRI scan results indicate that the lesion is invading into the muscularis but has not breached the full thickness, and there are no abnormal lymph nodes detected. Additionally, a contrast-enhanced CT scan of the chest and abdomen shows no signs of metastases. Biopsy results confirm the presence of adenocarcinoma. What is the most appropriate treatment for this patient?

The business launched a precautionary global recall of desmopressin formulations used to treat mild-to-moderate hemophilia A and von Willebrand disease after higher-than-specified amounts of desmopressin were discovered in various formulations. Stimate, a nasal spray containing a synthetic form of desmopressin acetate used to control bleeding in hemophilia patients, is among the recalled products, as is Octostim Nasal Spray 1.5 mg/ml, DDAVP 10 micrograms (mcg)/0.1 ml, Minirin Nasal Spray 0.1 mg/ml, and Generic Desmopressin Acetate Nasal Spray 10 mcg/0.1 ml. Products containing higher-than-specified amounts of desmopressin were recalled due to concerns that increased desmopressin exposure can result in water retention, low blood pressure, and low blood salt levels in mild cases, as well as seizure, coma, and death.

Anti-Xa levels could be helpful for determining current medication concentrations, determining the immediate safety of therapy, and providing direction for potential clinical actions. Further study is needed to determine how dose titration and reversal therapy based on anti-Xa level results in significant bleeding.

Twelve-hundred (1,200) patients admitted for 48 hours or more for COVID were randomized to 2.5mg of apixaban or placebo twice daily for 30 days. The incidence of death or thromboembolism was low and similar in the two arms of this study. The study was terminated early and the authors say the results are imprecise.